Atara Biotherapeutics Inc 's Cash & cash equivalent grew by 0.17 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Atara Biotherapeutics Inc 's Quick Ratio to 1.51, Quick Ratio remained below Atara Biotherapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 105 other companies have achieved higher Quick Ratio than Atara Biotherapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1391 to 1674.

Explain Quick Ratio?
How much Cash & cash equivalents ATRA�s has?
What are ATRA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ATRA/financial-strength

https://api.csimarket.com/api/v1/companies/ATRA/fundamentals

https://api.csimarket.com/api/v1/companies/ATRA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ATRA Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-63.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-27.68 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1.51	Subscribe	Subscribe	Subscribe	Subscribe
ATRA's Total Ranking	# 1674	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-4.07 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	0.17 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 106
Healthcare Sector	# 574
Overall Market	# 1674

Quick Ratio Statistics
High	Average	Low
51.82	12.59	0.24
(Sep 30 2015)		(Jun 30 2024)

Financial Statements
Atara Biotherapeutics Inc 's Current Liabilities	$ 7 Millions	Visit ATRA's Balance sheet
Atara Biotherapeutics Inc 's Cash & cash equivalent	$ 10 Millions	Visit ATRA's Balance sheet
Source of ATRA's Sales		Visit ATRA's Sales by Geography

Cumulative Atara Biotherapeutics Inc 's Quick Ratio

ATRA's Quick Ratio for the trailling 12 Months

ATRA Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-84.07 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-60.31 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.08	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4002	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-25.27 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-9.38 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ATRA Financial Strength Comparisons >> Go to Compare ATRA Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Atara Biotherapeutics Inc 's average Cash & cash equivalent, this led to increase in in Atara Biotherapeutics Inc 's Quick Ratio to 1.08, Quick Ratio remained below ATRA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Atara Biotherapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3863 to 4002.

Explain Quick Ratio?
How much Cash & cash equivalents ATRA�s has?
What are ATRA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 143
Healthcare Sector	# 900
Within the Market	# 4002

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.61	2.04	0.22
(Dec 31 2015)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Vir Biotechnology Inc	4.08	$ 454.635 Millions	$ 111.332 Millions
Moderna Inc	3.93	$ 7,976.000 Millions	$ 2,028.000 Millions
Immunocore Holdings Plc	3.93	$ 901.298 Millions	$ 229.619 Millions
Alector Inc	3.92	$ 138.697 Millions	$ 35.415 Millions
Dbv Technologies S a	3.89	$ 165.700 Millions	$ 42.600 Millions
Regenxbio Inc	3.71	$ 250.976 Millions	$ 67.684 Millions
Tenaya Therapeutics Inc	3.55	$ 66.797 Millions	$ 18.804 Millions
Intensity Therapeutics Inc	3.29	$ 8.494 Millions	$ 2.582 Millions
Adaptive Biotechnologies Corporation	3.02	$ 298.954 Millions	$ 98.967 Millions
Atyr Pharma Inc	2.96	$ 48.751 Millions	$ 16.463 Millions
Precision Biosciences Inc	2.90	$ 81.846 Millions	$ 28.258 Millions
Immunitybio inc	2.86	$ 334.329 Millions	$ 116.795 Millions
Editas Medicine Inc	2.66	$ 190.198 Millions	$ 71.582 Millions
Humacyte Inc	2.61	$ 64.523 Millions	$ 24.761 Millions
Autolus Therapeutics Plc	2.52	$ 248.377 Millions	$ 98.647 Millions
Vericel Corporation	2.44	$ 133.493 Millions	$ 54.719 Millions
Adma Biologics Inc	2.25	$ 124.555 Millions	$ 55.475 Millions
Cullinan Therapeutics Inc	2.20	$ 88.260 Millions	$ 40.130 Millions
Exelixis Inc	2.17	$ 892.018 Millions	$ 411.877 Millions
Halozyme Therapeutics Inc	2.12	$ 1,074.480 Millions	$ 506.173 Millions
Relay Therapeutics Inc	2.10	$ 124.184 Millions	$ 59.154 Millions
Biocryst Pharmaceuticals Inc	1.92	$ 375.334 Millions	$ 195.830 Millions
Novavax inc	1.89	$ 622.363 Millions	$ 329.845 Millions
Elutia Inc	1.81	$ 29.093 Millions	$ 16.030 Millions
Lenz Therapeutics Inc	1.78	$ 31.610 Millions	$ 17.750 Millions
Acumen Pharmaceuticals Inc	1.74	$ 78.604 Millions	$ 45.087 Millions
Sana Biotechnology Inc	1.63	$ 121.728 Millions	$ 74.880 Millions
Aligos Therapeutics Inc	1.59	$ 31.094 Millions	$ 19.600 Millions
Atara Biotherapeutics Inc	1.51	$ 9.917 Millions	$ 6.568 Millions
Tarsus Pharmaceuticals Inc	1.36	$ 309.612 Millions	$ 227.114 Millions

Date modified: 2026-11-11T18:29:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.